Items where authors include "Llewelyn, M.J."

Article

Bou-Antoun, S., Oettle, R.C., Leanord, A. et al. (16 more authors) (2025) Adaptation of the WHO AWaRe (Access, Watch, Reserve) antibiotic classification to support national antimicrobial stewardship priorities in the UK: findings from a modified Delphi approach to achieve expert consensus. JAC-Antimicrobial Resistance, 7 (1). dlae218. ISSN 2632-1823

Sandoe, J.A.T. orcid.org/0000-0003-0193-8677, Grozeva, D. orcid.org/0000-0003-3239-8415, Albur, M. et al. (138 more authors) (2024) A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19. Journal of Antimicrobial Chemotherapy, 79 (11). pp. 2792-2800. ISSN 0305-7453

Webb, E.J.D. orcid.org/0000-0001-7918-839X, King, N. orcid.org/0000-0002-4215-2323, Howdon, D. orcid.org/0000-0001-8052-2893 et al. (8 more authors) (2024) Evidence of quality of life for hospitalised patients with COVID-19: a scoping review. Health Technology Assessment. ISSN 1366-5278

Liu, X., Munro, A.P., Feng, S. et al. (56 more authors) (2023) Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]. Journal of Infection, 86 (5). pp. 540-541. ISSN 0163-4453

Euden, J. orcid.org/0000-0002-2844-6878, Pallmann, P. orcid.org/0000-0001-8274-9696, Grozeva, D. et al. (22 more authors) (2022) Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH): protocol for a retrospective observational study. Methods and Protocols, 5 (6). 95. ISSN 2409-9279

Munro, A.P.S., Feng, S., Janani, L. et al. (362 more authors) (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. The Lancet Infectious Diseases, 22 (8). pp. 1131-1141. ISSN 1473-3099

Liu, X., Munro, A.P.S., Feng, S. et al. (56 more authors) (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. Journal of Infection, 84 (6). pp. 795-813. ISSN 0163-4453